2. OTCQX BIOAF
TSX.V BTI
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not
be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”,
“estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or
information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future results, events or developments express or
implied by such forward-looking statements or information.
Such factors include, among others, our stage of development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our
products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for
negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and
uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or implied by such statements and information
include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or
clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to
fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate
collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our
products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at
www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements
and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and
information made herein are based on our current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
2"
4. OTCQX BIOAF
TSX.V BTI
Who we are…
Board of Directors
Rob Hutchison, Chair & CEO!
Former: CEO & Chief Scientist at eCharge Corporation
(World’s First Internet Payment System)
Chris Fibiger, PhD !
Former: Head of Neuroscience, Amgen; VP Neuroscience, Eli Lily &
CSO, Biovail Laboratories
!
Greg Gubitz, LLB!
Former: VP, Biovail Corporation (merged Valeant Pharmaceuticals)
COO, MDS Capital (Life Science VC firm $1bn under management)
Terry Pearson, PhD!
Professor: Biochemistry & Microbiology, UVIC
Bench-mates: Nobel Laureate, Dr. George Kohler (monoclonal antibody)
Discovered & commercialized highly- successful SISCAPA Assay
Technology !!
Ron Erickson !
Over 30 years experience: attorney & senior level executive
Current: Chair & CEO, Visulant Technologies (nano-photonics company)
Michael Hutchison, QC, LLB!
Partner, Smith Hutchison Law Corporation
Team!
!
Judi Dalling, LLB, CFO !
Over 35 years accountancy experience
Seasoned public company CFO and corporate lawyer
!
Wilfred Jefferies, PhD, Founding Scientist !
Oxford University, Molecular Immunology
Discovered p97’s ability to cross the BBB & Ox26 (foundational
antibody for BBB research)
Professor: Microbiology & Immunology, UBC
!
Reinhard Gabathuler, PhD, Chief Scientist!
University of Lausanne, Switzerland, Plant Biochemistry
Over 25 years experience, academic research & early-stage biotech
companies
Former: VP Brain Research, Biomarin & CSO, Angiochem Inc.
!
Mei Mei Tian, PhD, Scientist !
UBC, Microbiology and Immunology
Expertise in BBB transport, cell biology, molecular biology
!
Laura Ho, MSc, Scientist !
UBC, Microbiology and Immunology
!
Tiffany Tolmie, Corporate Communications !
Honours, Wilfrid Laurier University
5. OTCQX BIOAF
TSX.V BTI
What we do…
Brain Delivery Platform
Patented “Transcend Family” of technologies
allows drug therapies to penetrate the Blood-
Brain Barrier (“BBB”) to treat diseases of the
Central Nervous System (“CNS”)
Potential treatments for:
Market Leading Technology
Transcend & Transcendpep !
5"
Oncology
Metabolic
Diseases
Neurodegenerative
Diseases
6. OTCQX BIOAF
TSX.V BTI
The Blood-Brain Barrier Challenge
Blood Brain Barrier
Protective barrier of the CNS preventing toxic
compounds from entering the brain from the
circulatory system
Problem
BBB prevents therapeutics from entering the brain
• ~98% of small molecule drugs
• ~100% of large molecule drugs1
Solution
Discovering a ‘carrier’ to deliver therapeutic treatments
across the BBB
i. Opportunity to extend patent life of existing drug therapies
ii. Contribute to the growth in CNS drug market and revitalize
dormant candidates
iii. Assist development of new therapies for currently untreatable
diseases
6"
1) Royal Society of Chemistry
Tightly"woven"capillary"network"of"
endothelial"cells"lining"the"blood"vessels"
in"the"brain,"which"is"responsible"for"
maintaining"homeostasis"
7. OTCQX BIOAF
TSX.V BTI
Breakthrough Solution
First Generation: Transcend
• Known as Melanotransferrin (MTf or p97)
• Native human protein found at low
concentrations in the blood
• Technology patented at University of British
Columbia; later purchased by biOasis
7"
The Transcend Family
…is a naturally occurring physiological transport mechanism
… acts as a ‘Trojan-Horse’ to transport therapeutics across the BBB and into the brain tissue
Second Generation: Transcendpep
• A newly discovered peptide found within
Transcend, which offers improved brain
penetration over Transcend
8. OTCQX BIOAF
TSX.V BTI
Advantage of Transcendpep
Greater efficiency of BBB delivery
Lower cost of production
Improved quality control
Simpler to link to therapeutics
Transports a variety of compounds
with no apparent size limitation
Extends biOasis patent portfolio
Pharmaceutical collaborators
currently licensing Transcendpep
8"
BBB"
Transcendpep
Therapeutic
Transcendpep in Action
9. OTCQX BIOAF
TSX.V BTI
Market Opportunities
Major Unmet Medical Needs
Drug market limited by the BBB
9"
A carrier to
cross the
BBB would
establish a
foothold
within these
major
markets
Central
Nervous
System
~$81.2bn
Neuro-
degenerative
Diseases
~$20bn
!
Stroke &
Traumatic
Brain Injury
~$7.5bn
Pain &
Migraine
~$33.7bn
2014 Estimates in $USD
Clinical need met
but improved BBB
penetration could
increase efficacy
Psychiatry
~$32.3bn
Infection
(Bacterial, Viral, Fungal)
~$138bn
Lysosomal
Storage
Disease !
>$1.9bn
10. OTCQX BIOAF
TSX.V BTI
Brain Cancer Market
Sales for Current Cancer Therapeutics
Treatments for cancers, which frequently metastasize in the brain,
Do Not cross the BBB in efficacious levels
10"
1) GlobalData “Brain Tumor – Pipeline Assessment and Market Forecasts to 2017” released Jan. 17, 2011.
2) Company Reported Data
3) BT2111 Program Results slides 19 & 20
$0.9B
$2.1B
2009
2010
2011
2012
2013F
2014F
2015F
2016F
2017F
($ Billions)
Global Brain Tumor Therapies Market1
Herceptin®
(trastuzumab)
HER2+ Breast Cancer
Rituxan®
(Rituximab)
lymphomas,
leukemias
Taxol®
(Paclitaxel)
lung, ovarian,
etc.
Erbitux®
(Cetuximab)
Metastatic
colon cancer,
etc.
$92 million in
sales 20132
$7.5 billion in
sales 20132
$1.9 billion in
sales 20132
$6.6 billion
in sales
20132
Results
Trancend + Trastuzumab
(Herceptin®) conjugate
not only crossed the BBB
but increased cancer
killing activities
throughout the body3
Opportunity
Potential to increase
effectiveness of cancer
therapeutics and treat
tumours that metastasize
in the brain
$1.4 billion Market in 2013
11. OTCQX BIOAF
TSX.V BTI
Multiple Development Opportunities
Conjugated with Transcend:
• Antibodies
• Enzymes
• Biologics agents
• Small molecules drugs
Targeting:
11"
Patent Cliff
Estimated ~$250 billion in lost
revenue from patent expiration
between 2012-20151
Transcend family linked with
existing drugs offers the potential
for patent term extensions through
New Chemical Entity (“NCE”)
"
Specific brain cells
(e.g., neurons, astrocytes and
glia)
Intracellular compartments
(e.g., lysosomes, endosomes,
mitochondria)
Delivery into the brain of
existing therapeutic drugs
currently not approved for
CNS indications
Delivery into the brain of
promising new agents in
development
""
"
1)"DeRuiter,"J.,"&"Holston,"P."L."(2012,"June"20)."Drug"Patent"ExpiraOons"and"the"“Patent"Cliff”."U.S."Pharm."2012;37(6)(Generic"suppl):12Y20.""
12. OTCQX BIOAF
TSX.V BTI
Transcend: Rapid Uptake in Brain
12"
Compound
Brain Kin
(mL-1/s-1/g-1)
Reference
Glucose
9.5 x 10-3
Smith (2003)
Transcend
6.4 x 10-4
Demeule et al. (2002)
Morphine
2.0 x 10-4
Cisternino et al. (2001)
Aprotinin ! 1.6 x 10-4
Demeule et al. (2008)
Insulin Rec Antibody ! 1.0 x 10-4
Pardridge (1997)
Leu-Enkephalin
6.0 x 10-5
Zlokovic (1987)
Morphine-6-Glucuronide
2.4 x 10-5
Temsamani et al. (2005)
RAP ! 1.0 x 10-5
Pan (2004)
Beta Amyloid
6.5 x 10-6
Banks (1991)
DADLE
6.5 x 10-6
Chen (2002)
TNF-α
4.3 x 10-6
Pan (2002)
Transport
Efficiency
More
Less
In situ brain uptake – measurement of rate of transport
Competitors""
13. OTCQX BIOAF
TSX.V BTI
Independent
3rd party
validation
Expand and
protect
Intellectual
Property
portfolio
Advance
internal
development
programs
Collaborate
with reputable
pharmaceutical
companies
Corporate Strategy
13"
• Low-cost projects
• Potential to achieve
major milestones:
Short-Mid-Large
Market Potential
• Many “shots on
goal” leading to
commercial
transactions with
numerous strong
partners or
licensees
• Over 30 patents
granted relating to
Transcend &
Trancendpep for
BBB delivery and
neurodegenerative
diseases
• National Research
Council
• BC Cancer
Research Centre
• Texas Tech
University Health
Sciences Center
14. OTCQX BIOAF
TSX.V BTI
Development Programs
Completed 4 strategic collaborations on
First Generation Transcend:
• Shire HGT
• AbbVie
• MedImmune
• UCB Pharmaceuticals
Second Generation Transcendpep:
• MedImmune executed License Agreement
• On-going discussion with AbbVie & UCB
Pharmaceuticals for licensing
• Further discussions with large
pharmaceutical companies on licensing and
research opportunities
14"
15. OTCQX BIOAF
TSX.V BTI
Development Programs:
Transcend + Anti-Amyloid Beta (“Aβ”) Antibody
Results
!
Transcend + anti-Aβ antibody conjugate
increases transport into brain tissue by ~5-fold
0.000#
0.001#
0.002#
0.003#
0.004#
0.005#
0.006#
0.007#
Transcend3an43AB#mAb# an43Ab#mab#
Volume'Frac,on'''
Parenchyma#
Quantitative Image Analysis by Laser
Scanning Confocal Microscopy
15"
Alzheimer’s Disease
Anti-Aβ antibodies have
undergone clinical trials for
treatment of Alzheimer’s
disease
Opportunity
Using antibodies directed at
Aβ are potential
therapeutics for reducing
amyloid plaques in the brain
National Research Council of Canada (NRC)
Anti-Aβ
Transcend + Anti-Aβ
16. OTCQX BIOAF
TSX.V BTI
Development Program:
Transcend + α-L-iduronidase (“IDU”)
Lysosomal Storage Diseases
Rare inherited metabolic diseases caused by an
enzyme deficiency primarily affecting children
Hurler Syndrome (MPS I)
Problem
• MPS I is caused by an IDU deficiency
• Currently CNS effects untreatable
Results
• Transcend + IDU (lysosomal enzyme)
conjugate increased IDU brain enzyme
activity ~ 4-fold
Opportunity
• Offers promise of an enzyme replacement
therapy
16"
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
IDU
Transcend-IDU
Total"IDU"acOvity"
Capillaries
Parenchyma
17. OTCQX BIOAF
TSX.V BTI
Development Program:
Transcend + iduronate-2-sulfatase (“IDS”)
Lysosomal Storage Diseases
Rare inherited metabolic diseases caused by an
enzyme deficiency primarily affecting children
Hunters Syndrome (MPS II)
Problem
• MPS II is caused by an IDS deficiency
• Currently CNS effects untreatable
Results
• Transcend + IDS (lysosomal enzyme)
conjugate increased IDS brain enzyme
activity ~ 20-fold
Opportunity
• Offers promise of an enzyme replacement
therapy
17"
Native Enzyme
Transcend + IDS Enzyme
18. OTCQX BIOAF
TSX.V BTI
Development Program:
Transcend + Doxorubicin
• Doxorubicin is currently used as a
cancer treatment (e.g. non-Hodgkin's
lymphoma, multiple myeloma, acute leukemias,
etc.)
Problem
• Currently does not penetrate the BBB
Results
• Significant INCREASE in brain uptake with
the Transcend + Doxorubicin conjugate
VS Doxorubicin alone
Opportunity
• Would be highly effective in treating
brain tumors if it could be delivered into
the brain
18"
0.00"
1.00"
2.00"
3.00"
Transcend-Doxo
Doxo
% INJECTED DOSE
(G TISSUE/G BODY MASS)*100%
Transcend Significantly Enhances
Doxorubicin Transport into the Brain
Conjugate
retains full
activity once
released in
the brain
19. OTCQX BIOAF
TSX.V BTI
Transcend Significantly Reduces
Doxorubicin Uptake into the Heart
Problem
• Doxorubicin’s most serious
adverse effect is life-threatening
heart damage
Results
• Transcend + Doxorubicin VS
Doxorubicin on its own showed
a significant DECREASE in uptake
in the heart
Solution
• Could be used to treat brain
cancers and decrease heart-
uptake side effect, offering
increased usage
19"
0.0"
5.0"
10.0"
15.0"
20.0"
Transcend-Doxo
Doxo
%INJECTEDDOSE
(grambraintissue/grambodymass)*100
20. OTCQX BIOAF
TSX.V BTI
Development Program:
Transcend + Trastuzumab (Herceptin®)
• Trastuzumab (Herceptin®)1 is a
humanized monoclonal antibody
used to treat HER2+ breast cancer
• Annual global sales ~$6.6 bn2
• Increases survival rate but ~40%
patients eventually develop breast
cancer metastasis in the brain3
• Trastuzumab (Herceptin®) does
not cross the BBB
20"
1) Herceptin® is a registered trademark of Roche/Genentech
2) Company Reported Data – 2013
3) Britta Weigelt, Johannes L. Peterse & Laura J. van't Veer. (2005, August). Breast
cancer metastasis: markers and models. Nature Reviews Cancer 5 , 591-602.
Brain Capillaries
Cell Nuclei
BT2111: Transcend –
Trastuzumab (Herceptin®)
Confocal Image Performed by iCapture at St. Paul’s Hospital
Vancouver Canada
BT2111 Program: Transcend +
Trastuzumab (Herceptin®) conjugate
Confocal Images Two Hours Post IV Administration
21. OTCQX BIOAF
TSX.V BTI
Reduced the number of HER2+ breast
cancer tumors in the brain by 68%
The tumors that remained after
treatment were 57% smaller
BT2111: Transcend + Trastuzumab (Herceptin®)
In Vivo Efficacy in Breast Cancer Model
21"
…compared to those treated with Trastuzumab (Herceptin®) alone.
0"
10"
20"
30"
40"
50"
60"
70"
80"
90"
Number of Tumors
0.0"
0.5"
1.0"
1.5"
2.0"
2.5"
Mean Tumor Volume
Transcend""(MTF"or"p97)"
mm3!
22. OTCQX BIOAF
TSX.V BTI
Development Program:
Transcendpep + siRNA
Small Interfering RNA (siRNA)
• Silences target genes
• Nox4 is a gene associated with human diseases
(i.e. cancers, neurodegenerative diseases, metabolic diseases, etc.)
Problem
• siRNA does not cross the BBB
• Gene targeting within the brain is currently unachievable
Results
• Transcendpep + siRNA conjugate delivered into the brain tissue
• Demonstrated ~2 fold decrease in Nox4 signal VS siRNA
alone
Opportunity
• A potential cornerstone technology for the development of
new therapeutics suppressing disease-linked genes in the
brain
22"
National Research Council
NO siRNA detected in Brain
Transcendpep + siRNA
detected in Brain
23. OTCQX BIOAF
TSX.V BTI
Highlights
23"
Transcend Family
“…would be the first carrier to
efficaciously shuttle
compounds across the BBB”
Discovery of Transcendpep
• Enhanced technology
• Greater commercialization
potential
Company Profile
• Good cash position
• Clean share structure
• High internal ownership
• Strong IR Program
• Exit strategy in place
Management
Major success in:
• Drug commercialization
• Academia (BBB &
monoclonal antibodies)
• Biotechnology & venture
capital startups
IP & Collaborations
• Full patent protection
• Large pharmaceutical
collaborations
• Positive results;
demonstrated efficacy
Large Market Opportunities
• Ability to extend patent life
• Commercialize new
therapeutics and/or revitalize
dormant candidates
• Contribute to the growth in
CNS drug market
Treatment Potential
• Oncology
• Metabolic diseases
• Neurodegenerative diseases
…among others
24. OTCQX BIOAF
TSX.V BTI
Timeline 2014-2015
Milestones Achieved
! Proof of principle
demonstrated
! Discovery of
Transcendpep -
extended patent
protection
! Strong
pharmaceutical
collaborations
! Completion of
necessary financings
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Leader in
providing
shareholder
value
Awarded
TSX.V
Top 50®
"
Financing: TBD
Licensing: Transcendpep
Collaborations: New research and/or licensing agreements
External R&D: Development of New R&D Programs
Internal R&D
BT2211 & LSD Programs
Animal efficacy studies
Internal R&D
Pre IND Toxicity Studies
Proposed IND Filing
Evaluation: Exit strategies:
Licensing / M&A
2014! 2015!
